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ABSTRACT 
Purpose: Cancer-related fatigue negatively impacts quality of life and possible recurrence and 
overall mortality in breast cancer survivors.  This study aimed to investigate the associations 
between inflammation and cancer-related fatigue in breast cancer survivors using methods of 
systematic review and quantitative assessment of the Hormones and Physical Exercise (HOPE) 
Study in a high-risk population.  Methods: A PubMed search was conducted to identify peer-
reviewed studies that assessed the associations among inflammatory markers, CRP, IL-6, and 
TNF-, and cancer-related fatigue in breast cancer survivors.  The HOPE Study was a 
randomized control trial in 121 postmenopausal Stage I-IIIC breast cancer survivors, who were 
taking Aromatase Inhibitors (AIs) and experiencing arthralgia.  This study investigated the 
associations of baseline (N = 69) pro-inflammatory markers CRP, IL-6, and TNF- and self-
reported fatigue.  Results: Fifteen studies with more than 1,900 participants were included in the 
systematic review.  The literature inconclusively supported the CRP and cancer-related fatigue 
association.  TNF- and IL-6 were not associated with cancer-related fatigue.  In the HOPE 
Study, CRP, IL-6, and TNF-, fatigue, and sleep duration were not significantly associated.  
There was the suggestion of a positive trending association between CRP and cancer-related 
fatigue among women with higher stage of disease.  BMI status and joint pain intensity were 
significant risk factors of cancer-related fatigue.  Conclusion: A growing body of literature 
inconclusively supports the link between downstream inflammatory activity and cancer-related 
fatigue.  There may be subgroups of women, e.g. those with higher stage of disease, for whom 
this may be particularly important.  A further understanding of cancer-related fatigue 
mechanisms and the development of effective interventions are necessary to improve the quality 
and duration of life in the increasing population of cancer survivors. 
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INTRODUCTION 
Cancer-related fatigue is the most common and distressing symptom reported by women 
diagnosed with breast cancer,
1-3
 even more distressing than cancer-related pain, nausea, or 
vomiting.
4
  Prevalence estimates of cancer-related fatigue range from 25% to 99%, depending on 
the sample, treatment type, and assessment methodology,
5
 with more than 60% of cancer 
survivors reporting moderate to severe fatigue.
6
  While fatigue often improves within a year 
following treatment, cancer-related fatigue may continue months and years after successful 
completion of treatment.  One third of those in remission experience cancer-related fatigue for up 
to 10 years post-cancer diagnosis, and 40% to 50% report sleep disturbance.
7
  Insomnia is a 
strong predictor of cancer-related fatigue, and over 50% of cancer patients experience sleep 
disturbance (difficulty falling asleep and maintaining sleep, awakening too early from sleep, and 
daytime sleepiness), as confirmed by polysomnographic data.
8
  However, cancer-related fatigue 
is more chronic and debilitating than non-cancer-related fatigue and is not relieved with adequate 
sleep.
9
 
 
Not only does cancer-related fatigue negatively impact mental and physical wellbeing and 
overall quality of life,
1
 but cancer-related fatigue may also be associated with recurrence (p = 
0.0004) and overall mortality (p = 0.0101) in newly diagnosed breast cancer patients (N = 1,588) 
followed for a median of 12.9 years.
10
  While this finding has not been repeated in the literature 
[possibly due to methodology, smaller sample sizes (N = 398 and N = 448, respectively), and 
shorter median follow-up (5.8 and 5.5 years, respectively)],
11,12
 identifying the mechanisms 
behind cancer-related fatigue will significantly advance the development of targeted 
interventions and improve the lives of cancer survivors.   
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Cancer-related fatigue has a complex etiology.
13
  While white blood cell count and hemoglobin 
do not fully explain cancer-related fatigue, recent studies support the role of inflammatory 
mediators in cancer-related fatigue, as these mediators are often elevated in cancer patients and 
are known to induce fatigue.
1
  The innate immune response has been shown in animal and 
human studies to induce “sickness behavior,” which includes depression, fatigue, impaired sleep, 
and cognitive dysfunction.
8
  This may be the result of cytokine-induced inflammatory responses 
within the brain that are associated with metabolic alteration and synaptic availability of relevant 
neurotransmitters, including serotonin, norepinephrine, and dopamine.
8
  Additional mechanisms 
involved in the link between inflammation and cancer-related fatigue may include: 1) genetic 
polymorphisms (single-nucleotide polymorphisms in cytokine genes, e.g. polymorphisms in 
TNF- and IL-6 were associated with cancer-related fatigue in breast, prostate, and lung cancer 
patients),
14-17
 2) alterations in the hypothalamic-pituitary-adrenal axis and alterations in immune 
factors (e.g. cellular immune system and latent herpes viruses), and 3) biobehavioral factors (e.g. 
history of depression, sleep disturbance, early life stress, and body mass index).
1
   
 
The purpose of this study was to examine the associations between inflammation and cancer-
related fatigue using 1) methods of systematic review [to update the Saligan et al (2012) review
18
 
and focus on breast cancer survivors] and 2) quantitative, observational data analysis in a high 
risk population: breast cancer survivors taking AIs and experiencing arthralgia.  AIs cause 
arthralgias and myalgias of elusive etiology suggestive of inflammatory association.
19
  AIs have 
been shown to improve disease-free survival in postmenopausal women diagnosed with 
hormone-receptor positive disease, by significantly lowering estrogen levels.  AIs are now the 
current standard of care for treating hormone receptor-positive breast cancer.
20
  The most 
 Foss 8 
common side effect of AIs, arthralgia or joint pain, may cause increased inflammation, cancer-
related fatigue, and poor sleep habits. To our knowledge, no study has examined the relationship 
between inflammation and cancer-related fatigue in breast cancer survivors taking AIs.  
 
We conducted the National Cancer Institute funded “Hormones and Physical Exercise (HOPE) 
Study,” a randomized control trial examining the effect of 12 months of moderate-intensity 
aerobic and resistance training exercise vs. usual care on improving side effects of aromatase 
inhibitors, including arthralgia severity, endocrine-related quality of life, and bone mass, in 
women taking AIs and reporting arthralgia.  Baseline data on inflammation, cancer-related 
fatigue, and sleep were obtained from all women enrolled.  The purpose of this analysis was to 
examine the baseline cross-sectional associations among the inflammatory markers, C-reactive 
protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor- (TNF-), and cancer-related 
fatigue in breast cancer survivors taking AIs and enrolled in the HOPE Study.  As this population 
may have an increased risk for inflammation, assessing the association between inflammatory 
levels and fatigue and sleep could be critical to treatment adherence and the development of 
targeted interventions. 
 
METHODS 
Systematic Review 
PubMed was utilized to identify relevant studies.  MeSH headings “c-reactive protein AND 
fatigue AND breast cancer,” “interleukin AND fatigue AND breast cancer” and “tumor necrosis 
factor AND fatigue AND breast cancer” were utilized to identify studies.  Inclusion criteria 
included the following: English-language and quantitative assessment of the associations 
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between inflammatory markers CRP, IL-6, and/or TNF- and cancer-related fatigue in breast 
cancer survivors. 
 
HOPE Study 
Participants 
The study enrolled 121 postmenopausal AJCC Stages I-IIIC hormone receptor positive breast 
cancer survivors under the age of 76 years who had been taking an AI for at least six months and 
were currently experiencing at least mild arthralgia associated with AI use (defined as  3 on the 
Brief Pain Inventory Short Form Questionnaire).
21
  Eligible participants were physically inactive 
(< 90 mins/week of moderate-to-vigorous intensity aerobic exercise and no strength training 
within the past year), were able to exercise, agreed to random assignment, provided informed 
consent to participate in all study activities, were mentally competent, and were able to come for 
baseline, 6-, and 12-month clinic visits and twice-weekly strength training sessions.  The 
exclusion criteria included a history of other malignancies (other than non-melanoma skin cancer 
or in situ cervical cancer) or recurrence of breast cancer.   
 
Recruitment 
Women diagnosed with hormone receptor positive breast cancer at one of four Connecticut (CT) 
hospitals: 1) Smilow Cancer Hospital at Yale-New Haven, 2) Hospital of St. Raphael, 3) 
Bridgeport Hospital, and 4) Greenwich Hospital, were recruited through the Rapid Case 
Ascertainment (RCA) Shared Resource of the Yale Cancer Center, a field arm of the CT Tumor 
Registry.  The RCA provided a list of potential participants and their physicians.  Upon receipt of 
physician approval, invitation letters, detailing the study and informing the potential participant 
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of a phone call from the Principal Investigator to solicit interest and eligibility within a week, 
were mailed to potential participants.  Eligibility was assessed via phone, and eligible 
participants received a baseline clinic visit.  A total of 1,020 screening telephone calls were 
completed between April 1, 2010, and December 23, 2012, and 121 participants were enrolled in 
the study (Figure 1). 
 
Measures 
This study utilized HOPE baseline data, where participants completed questionnaires and were 
subject to physical measurements and a fasting (> 12 hours) blood draw.  Three sets of measures 
were used in this secondary analysis: inflammatory biomarkers, cancer-related fatigue, and sleep, 
and the demographic measures and covariates assessed include: age, BMI, race/ethnicity, 
education, cancer stage at diagnosis, treatment (radiation and/or chemotherapy), pain intensity 
(as measured by the Brief Pain Inventory) and time since cancer diagnosis.   
 
Demographics and Medical History 
Baseline visit information was collected via an interviewer-administered questionnaire.  All 
medical history information was self-reported and later confirmed by the participant’s physician 
and medical record review. 
 
Anthropometry 
Height without shoes was measured using a stadiometer.  Weight with light clothing and without 
shoes was measured on a digital scale.  Height and weight measurements were the average of 
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two measurements taken in succession by the same technician and were rounded up to the next 
0.5 cm and 0.1 kg, respectively. 
 
Fatigue 
Fatigue was measured using the Functional Assessment of Cancer Therapy fatigue subscale 
(FACIT-F).  FACIT-F is a 13 item questionnaire assessing fatigue with high internal consistency 
(Cronbach’s  = 0.93-0.95),22,23 convergent and discriminant validity revealing a positive 
correlation with other fatigue-questionnaires, and was found to be stable on test-retest (r = 
0.87).
23
 
 
Sleep 
Sleep was measured using an abbreviated, 8-item, Pittsburgh Sleep Quality Index (PSQI).  PSQI 
has high overall reliability and internal consistency (Cronbach’s  = 0.83) and validity 
(MANCOVA p < 0.001) and has a specificity and sensitivity of 89.6% and 86.5%, respectively 
(kappa = 0.75, p < 0.001).
24
 
 
Inflammation 
The serum inflammatory measures assessed include: CRP, IL-6, and TNF-.  Serum samples 
were collected, centrifuged at 2,000 rpm for 15 minutes at 4˚C, separated into plasma and buffy 
coat, stored temporarily for transportation at -20˚C, and stored at -70˚C until analyzed.  Samples 
were measured in duplicate to improve reliability, and quality control samples were included in 
each batch.  CRP was measured with an ACE chemistry analyzer (Alfa Wassermann Inc).  IL-6 
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and TNF-α were determined by enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis, MN). 
 
Statistical Analysis 
The analyses were carried out with SAS for Windows PC, version 9.2.  Descriptive 
characteristics are presented as means and standard deviations for continuous variables and 
number and percentage of total for categorical variables.  Pearson correlations were performed to 
determine the associations between inflammatory biomarkers, cancer-related fatigue, and sleep 
duration.  Given the larger published evidence supporting a potential relationship between CRP 
and fatigue, we determined unadjusted and adjusted associations between CRP tertiles and 
FACIT-fatigue scores using linear regression.  The adjustment covariates included:  age, BMI, 
cancer stage at diagnosis, radiation, chemotherapy, pain intensity, and time since cancer 
diagnosis, with stratification variables removed in respective adjustments.  We repeated these 
analyses stratified by a priori determined factors: cancer stage at diagnosis, radiation, 
chemotherapy, BMI status, and pain intensity.  Additionally, adjusted and unadjusted linear 
regressions were performed to determine which covariate(s) (cancer stage at diagnosis, radiation, 
chemotherapy, BMI status, pain intensity, and sleep quality) were the greatest risk factor(s) of 
fatigue.  Pearson correlation coefficients and linear regression adjusted and unadjusted p values 
denote the strength of associations.  The significance level was set at p < 0.05.  All tests were 
two-sided.  
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RESULTS 
Systematic Review 
As of April 22, 2013, forty-five total studies were identified through the initial search, twelve of 
which were excluded due to duplication (three studies in triple duplicate)
7,17,25-37
 and thirty of 
which were examined for inclusion (Figure 2).
7,17,25-52
  Thirteen citations were excluded at the 
title and abstract level
26,30,34,39,40,42,44-49,51
 and two studies were excluded at the full article 
review
36,50
 for not meeting the inclusion criteria.  Fifteen were included in the systematic review. 
 
A growing body of literature supports the hypothesis that downstream inflammatory activity, e.g. 
soluble tumor necrosis factor receptor Type II (sTNF-RII), interleukin-1 receptor antagonist (IL-
1RA), and C-reactive protein (CRP), are associated with cancer-related fatigue.
1
  The literature 
cites 15 studies in this field related to the inflammatory biomarkers CRP, IL-6, and TNF- and 
cancer-related fatigue in breast cancer survivors (Table 1).  CRP was significantly and positively 
associated with many factors of fatigue: fatigue duration, behavioral changes due to fatigue, 
emotional meaning and symptoms of fatigue, and total fatigue [ = 0.32; SE = 0.14; p = 0.022],27 
[all p < 0.02],
38
 [ = 0.120, p = 0.020],33 [p = 0.003],35 [r = 0.47, p = 0.004],32 [Spearman’s 
correlation coefficient-0.456, p < 0.01]
52
 (Table 1 & 2).  In other studies, however, CRP, was 
only associated with total nighttime wake time but was not associated with total fatigue, total 
sleep, total nighttime sleep time, or total nap time in newly diagnosed breast cancer survivors 
scheduled to receive chemotherapy,
31
 in breast cancer patients three months post primary cancer 
treatment,
7
 or in those newly diagnosed.
28
  The association between IL-6 and fatigue are unclear.  
IL-6 is shown to be positively associated ( = 14.027, SE = 4.194, p = 0.002),31 negatively 
associated (Spearman’s correlation coefficient = 0.311, p = 0.05),52 and not associated with 
 Foss 14 
fatigue.
27,29,41,43,53
  While sTNF-RII has been shown to be significantly associated with fatigue,
25
 
TNF- has not.29,37,41,43,52  
 
HOPE Study 
Baseline Characteristics 
As of April 10, 2013, baseline inflammatory data were available for the first 69 women enrolled 
into the HOPE Study.  Among the 69 women included in this analysis, study participants were an 
average of 61.8 years (Table 3).  The majority of participants were non-Hispanic white (89.9%) 
and college graduates or above (50.7%).  Approximately two-thirds of participants were 
overweight (36.2%) or obese (37.7%), with an average BMI of 29.5 kg/m
2
.  The majority of 
participants were diagnosed with Stage I cancer (62.3%) and had received chemotherapy 
(53.6%).  Only 20.3% of participants had received radiation therapy.  The average time since 
diagnosis was 3.04  2.14 years. Participants slept, on average, 6.5 hours per night and described 
their sleep quality as follows: very good (10.2%), fairly good (50.7%), fairly bad (34.8%), and 
very bad (2.9%).  On a scale from 0 to 52, with a higher score denoting better quality of life, the 
average participant FACIT-Fatigue score was 37.4.  Mean serum CRP was 3.1 mg/L.  HOPE 
Study participants had higher inflammatory markers and fatigue (lower FACIT-fatigue scores), 
as compared to a normal, healthy population (Table 4). 
 
Fatigue, Inflammation, and Sleep 
There was no association between FACIT-fatigue scores, CRP, IL-6, TNF-, and sleep hours 
(Pearson’s correlation, p > 0.05, data not shown).  Overall, CRP tertiles were not significantly 
associated with cancer-related fatigue in both the adjusted and unadjusted linear regression 
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models (p > 0.05) (Table 5).  When stratified by covariates, associations between CRP tertiles 
and cancer-related fatigue were significant and moderately significant in those with higher stage 
of disease at diagnosis in the unadjusted (p = 0.019) and adjusted (p = 0.080) models, 
respectively.  All other stratified analyses were non-significant.  BMI status (unadjusted p = 
0.013) and pain intensity (unadjusted p = 0.002, adjusted p = 0.011) were significant risk factors 
of cancer-related fatigue (Table 6). 
 
DISCUSSION 
A growing body of literature supports the hypothesis that downstream inflammatory activity, e.g. 
C-reactive protein (CRP),
27,32,33,35,38,52
 is associated with cancer-related fatigue, yet the data is not 
entirely conclusive.
1
  The association between IL-6 and fatigue is unclear (with evidence to 
support positive,
31
 negative,
52
 and no association
27,29,43,53
), and TNF- is consistently not 
associated with fatigue.
29,37,43,52
  Limitations to these studies include small sample 
sizes,
25,27,29,31,32,37,41,43,52,53
 potential selection bias towards healthier, less fatigued individuals,
28,38
 
and not assessing the associations between inflammation, fatigue, and sleep as the primary 
outcome.
41
  Further, many studies did not adjust for BMI or cancer stage at diagnosis, and none 
adjusted for pain. 
 
Our study examined associations among inflammation, cancer-related fatigue, and sleep in a 
sample of breast cancer survivors at high risk for inflammation, lack of sleep, and fatigue, given 
participants had been experiencing arthralgia originating during AI treatment.  Our findings 
showed no significant association between cancer-related fatigue, CRP, IL-6, TNF-, and sleep 
hours, adjusting for potential confounders.  However, the data suggested an association between 
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cancer-related fatigue and CRP among women with higher stage disease, and BMI status and 
pain intensity were the most significant predictors of cancer-related fatigue. 
 
While this study assessed a potentially higher risk population due to arthralgia, the mechanisms 
of AI-associated arthralgia are unclear but suggest estrogen deprivation as an etiologic 
explanation.  While AI-induced arthralgia is associated with normal levels of CRP, estrogen 
deficiency results in elevated IL-6 and TNF-.54  Normalized CRP levels may contribute to this 
population’s CRP homogeneity, as compared to previously published studies demonstrating a 
fatigue-CRP association.
33,35,38
  Non-steroidal anti-inflammatory drugs are the most widely used 
treatment for arthralgia and may further homogenize the study population with regards to 
circulating inflammatory markers.
54
  Further, statins suppress CRP at the transcriptional level 
and may contribute to lower, more homogenous CRP levels among HOPE study participants.
55
  
 
Limitations include the lack of variability in the fatigue and CRP scores, lack of adjustment for 
anti-inflammatory, statin, and pain medications, as well as the fact that the cross-sectional study 
design precludes the establishment of temporal or causal relationships.  However, a significant 
study strength is that this is the first study to examine the associations among inflammation and 
fatigue in this high-risk population.   
 
While Groenvold et al (2007) show that cancer-related fatigue predicts recurrence and overall 
mortality in breast cancer patients,
10
 the principle mechanisms underlying this relationship 
remain unclear and may derive from biological (e.g. inflammation), psychological (e.g. 
depression), or process (e.g. medication compliance) factors.  Our data indicate that there may be 
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subgroups of women, e.g. those with higher stage of disease, who may serve to benefit from 
inflammation-reducing interventions.  Further, as our data demonstrated that BMI status and pain 
intensity are the strongest predictors of fatigue, future studies should assess the affects of weight 
loss and pain management interventions on cancer-related fatigue, recurrence, and survivorship.  
While a growing body of literature supports the link between downstream inflammatory activity 
and cancer-related fatigue, future research is required to understand the mechanisms and causal 
pathway underlying these associations.
1
  A better understanding of cancer-related fatigue and the 
subsequent development of effective interventions will serve to improve the duration and quality 
of life in an increasing population of cancer survivors.
56
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APPENDIX 1 
 
FACIT-fatigue 
 
Below is a list of statements that other people with cancer have said are important to their 
quality of life.  Please indicate the extent to which you have experienced each of the 
statements during the past 7 days by circling the appropriate number using the following 
scale. 
 
During the PAST WEEK:   
0 1 2 3 4 
Not at all A little bit Somewhat Quite a bit Very Much 
 
FATIGUE AND ENERGY 
1.   I feel fatigued 0       1       2       3       4 
2.   I feel weak all over 0       1       2       3       4 
3.   I feel listless (“washed out”) 0       1       2       3       4 
4.   I feel tired 0       1       2       3       4 
5.   I have trouble starting things because I am tired 0       1       2       3       4 
6.   I have trouble finishing things because I am tired 0       1       2       3       4 
7.   I have energy  0       1       2       3       4 
8.   I am able to do my usual activities 0       1       2       3       4 
9.   I need to sleep during the day 0       1       2       3       4 
10. I am too tired to eat 0       1       2       3       4 
11. I need help doing my usual activities 0       1       2       3       4 
12. I am frustrated by being too tired to do the things I want to do 0       1       2       3       4 
13. I have to limit my social activity because I am tired 0       1       2       3       4 
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Table 1: Associations between inflammatory markers, fatigue, and sleep 
 
Study Design Participants Measures Results  
 
Alfano et al 
2012 
Multicenter 
prospective cohort 
study (HEAL Study); 
assessed 
inflammation 
biomarkers (30 
months after 
diagnosis) and fatigue 
measures (39 months 
after diagnosis) 
Stage I to IIIA breast 
cancer survivors (n = 
633) with a mean age of 
56 years 
Inflammatory: 
CRP and SAA 
 
Fatigue: 
Revised Piper Fatigue 
Scale Short Form-36 
(assess severity of fatigue) 
 
Covariates: age, race/study 
site, tamoxifen use, 
menopausal status 
Higher CRP levels were 
significantly and linearly 
associated with higher behavioral 
(ptrend = 0.003), sensory (ptrend = 
0.001), and total fatigue (ptrend = 
0.02), which were attenuated after 
adjusting for medication use, 
comorbidity, and BMI. 
Cameron et al 
2012 
Nested case-control 
study derived from a 
prospective cohort 
study where 
participants were 
assessed before, 
during, and after 
adjufant treatment 
Early-stage breast cancer 
survivors (n = 28, 13 
cases with confirmed 
post-cancer fatigue and 
15 controls who did not 
develop post-cancer 
fatigue) 
Inflammatory: 
IL1, IL2, IL4, IL6, IL10, 
IL12, TNF-, IFN-, 
neopterin, IL1ra, sIL6R, 
sTNF-rII, leukocytes 
 
Fatigue: 
Somatic and Psychological 
Health Report (SPHERE, 
43-item tool with a fatigue 
subscale, the SOMA) 
 
Sleep:  
Sleep Assessment 
Questionnaire 
 
Covariates: none 
mentioned 
Cytokine levels did not 
significantly differ between cases 
and controls (all p > 0.01). 
Fagundes et al 
2012 
Cross-sectional Newly diagnosed breast 
cancer survivors or those 
awaiting a positive 
diagnosis result (n = 
158) 
Inflammatory: 
CRP 
 
Fatigue:  
RAND SF-36 
vigor/vitality scale  
 
Sleep: 
Insomnia Severity Index 
 
Covariates: none 
mentioned 
CRP was not statistically 
associated with being fatigued, as 
compared to not being fatigued (p 
= 0.88). 
Liu et al 2012 Prospective; data was 
collected at baseline 
and during cycles 1 
and 4 of 
chemotherapy 
Newly diagnosed, stage 
I-III breast cancer 
survivors scheduled to 
receive adjuvant or 
neoadjuvant 
anthracycline-based 
chemotherapy and with a 
mean age of 50.3 years 
(n = 53). 
Inflammatory: 
IL6, IL1RA, CRP 
 
Fatigue: 
Multidimensional Fatigue 
Symptom Inventory-Short 
Form 
 
Sleep: Pittsburgh Sleep 
Quality Index (PSQI); 
Actillume actigraph data 
hand-edited with 
additional self-report sleep 
log information 
 
CRP was significantly associated 
with total nighttime wake time ( = 
0.774, SE = 0.261, p = 0.01), but 
was not significantly associated 
with total MFSI-SF score, total 
PSQI score, total nighttime sleep 
time, or total nap time. 
 
IL6 was significantly associated 
with total MFSI-SF score ( = 
14.027, SE = 4.194, p = 0.002) and 
total PSQI score ( = 1.740, SE = 
0.690, p = 0.02).   
 
IL1RA was significantly associated 
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Covariates: time, race, use 
of antacids (in 
inflammatory marker and 
MFSI-SF association) 
with total PSQI score ( = 0.974, 
SE = 0.423, p = 0.03). 
Bower et al 
2011 
Cross-sectional Stage 0-IIIA breast 
cancer survivors, 3 
months post primary 
cancer treatment 
completion but prior to 
endocrine therapy (n = 
103) 
Inflammatory: 
IL1RA, TNF, sTNF-RII, 
CRP 
 
Fatigue: 
Fatigue Symptom 
Inventory  
Sleep: 
 Pittsburgh Sleep Quality 
Index  
 
Covariates: age, time since 
diagnosis, cancer treatment 
prior to gene analysis 
Fatigue was not associated with 
IL1RA or CRP (both p > 0.9). 
Orre et al 2011 Cross-sectional; 
participants assessed 
at a mean 4 years post 
diagnosis 
breast cancer survivors 
treated with 
postoperative 
locoregional 
radiotherapy for stage II-
III breast cancer with a 
mean age of 55 years (n 
= 299) 
Inflammatory:  
Hemoglobin, leukocytes, 
hsCRP, sTNF-R1 
 
Fatigue: 
Fatigue Questionnaire 
(FQ; 11-items assessing 
both physical and mental 
fatigue) 
 
Sleep:  
Insomnia symptoms (2-
items) 
 
Covariates: age, 
educational level 
Of the inflammatory biomarkers 
assessed, only hsCRP was 
significantly and positively 
associated with total fatigue, 
adjusted ( = 0.120, p = 0.020).  
Insomnia was significantly 
associated with fatigue ( = 0.236, 
p < 0.001). 
Reinertsen et al 
2011 
Cross-sectional Stage II/III breast cancer 
survivors under the age 
of 75 (n = 302) 
Inflammatory: 
Leukocytes, CRP 
 
Fatigue: 
Fatigue questionnaire (7-
item tool to assess both 
mental and physical 
fatigue) 
 
Covariates: treatment 
strategies, BMI, treatment-
area related fibrosis 
CRP was significantly associated 
with both chronic fatigue (p = 
0.003) and persistent fatigue (p < 
0.001), as compared to those 
without chronic fatigue and those 
never fatigued, respectively. 
Lyon et al 2010 Prospective, three-
group (cranial 
electrical stimulation 
[CES], CES-sham, 
control), randomized, 
double-blinded, 
longitudinal pilot 
feasibility study 
Stage I-IIIA breast 
cancer survivors 
receiving adjuvant 
chemotherapy or 
neoadjuvant therapy 
with an anthracycline-
containing 
chemotherapy regimen 
(n = 36) 
Inflammatory: 
IL6, TNF-, IL-1, CRP 
 
Fatigue: 
Brief Fatigue Inventory  
 
Sleep: 
General Sleep Disturbance 
(GSDS, 21-item tool, 
assesses frequency of sleep 
problems) 
 
Covariates: none 
mentioned 
 
Fatigue was significantly 
associated with CRP (r = 0.47, p = 
0.004). 
Bower et al Prospective cohort Newly diagnosed breast  Inflammatory: Fatigue duration: 
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2009 study; assessed self-
report fatigue and 
sleep measures and 
inflammation 
biomarkers before, 
during, and after a 
course of radiation 
therapy 
(n = 28) or prostate 
cancer (n = 20) survivors 
25-75 years of age 
undergoing radiation 
therapy 
Serum IL1, IL6, IL1 
receptor antagonist, CRP 
 
Fatigue: 
Fatigue Symptom 
Inventory  
 
Sleep: 
Medical Outcomes Study 
Sleep Scale  
 
Covariates: sleep 
disturbance, depressive 
symptoms, age, BMI, 
hormone therapy 
IL1 and IL6 were not associated 
with fatigue (all Ps > 0.30).  CRP 
was significantly associated with 
fatigue duration ( = 0.32; SE = 
0.14; p = 0.022).  The association 
remained significant after 
controlling for sleep disturbance, 
depressive symptoms, age, body 
mass index, and hormone therapy. 
 
Fatigue severity: 
IL1 receptor antagonist was 
associated with increased fatigue 
severity ( = 0.63, SE = 0.26, p = 
0.016) controlling for sleep and 
depression measures, age, body 
mass index, and hormone therapy. 
Von Ah et al 
2008 
Prospective 
longitudinal cohort 
study; assessed 
measures before, 
during, and after 
adjuvant therapy 
Newly diagnosed stage 
0-IIIA breast cancer 
survivors at least 1 week 
post surgery but prior to 
adjuvant therapy (n = 
57) 
Inflammatory: 
IL-1, TNF- 
 
Fatigue: 
Piper Fatigue Scale-
Revised  
 
Covariates: type of 
adjuvant therapy, mood, 
network support, 
satisfaction, cortisol, 
perceived stress, optimism 
Before adjuvant therapy, IL1 was 
significantly associated with 
cancer-related fatigue ( = 0.35, p 
< 0.01). 
Bower et al 
2007 
Longitudinal cohort 
study 
Stage 0-II breast cancer 
survivors (N = 25, 10 
fatigued and 15 non-
fatigued) 
Inflammatory: 
IL-6, TNF- 
 
Fatigue: 
SF-36 Validity Scale 
 
Covariates: time between 
blood draw, age, marital 
status, cancer treatment, 
BMI, depressed mood 
score 
IL-6 and TNF- did not 
significantly differ among those 
fatigued and not-fatigued at 
baseline. 
Collado-
Hidalgo et al 
2006 
Case-control study Breast cancer survivors 
originally diagnosed 
with stage 0-II breast 
cancer, completed all 
cancer treatment, and 
were 1-5 years post 
diagnosis (n = 50, 32 
fatigued cases, 18 
nonfatigued controls) 
Inflammatory: 
Plasma IL6, sIL6R, IL1ra, 
TNF-rII, monocyte 
intracellular production of 
IL6 and TNF- 
 
Fatigue status: 
Validity scale of the SF-36 
 
Covariates: age, BMI, time 
since treatment, treatment 
mode, depressive symptom 
scores 
Plasma IL6 did not significantly 
differ between cases and controls. 
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Wratten et al 
2004 
Prospective cohort 
study 
Breast cancer survivors 
(n = 52) 
Inflammatory: 
Transforming growth 
factor-, fibroblast growth 
factor-, IL6, TNF-, 
intercellular adhesion 
molecule-1, platlet derived 
growth factor, CRP 
 
Fatigue: 
FACT fatigue subscale 
(subscale of FACT G 
quality-of-life 
questionnaire, a 13-item 
tool assessing fatigue 
severity) 
 
Covariates: BMI 
The baseline values of CRP 
(Spearman’s correlation 
coefficient-0.456, p < 0.01) and 
IL6 (Spearman’s correlation 
coefficient -0.311, p = 0.05) were 
significantly correlated with 
baseline values of fatigue. 
 
The week 5 CRP values 
(Spearman’s correlation coefficient 
-0.215, p = 0.19) were not 
correlated with fatigue, but the 
week 5 IL6 values were 
(Spearman’s correlation coefficient 
-0.367, p = 0.03). 
Bower et al 
2002 
Cross-sectional Stage 0-II (at diagnosis) 
breast cancer patients 1-
5 years post diagnosis 
who completed adjuvant 
therapy and were 
currently disease free (n 
= 40) 
Inflammatory: 
IL-1, IL-1RA, sTNF-RII, 
neopterin, lymphocytes 
 
Fatigue: 
RAND 36-Item Health 
Survey fatigue subscale (4-
item) and Fatigue 
Symptom Inventory (13-
item) 
 
Covariates: caffeine, 
alcohol use, smoking 
Compared with non-fatigued  
breast cancer survivors, fatigued 
breast cancer survivors had 
significantly higher levels of IL-
1RA (p = 0.006), neopterin (p = 
0.018), and sTNF-RII (p = 0.005). 
Geinitz et al 
2001 
Prospective cohort 
study; participants 
were assessed at 5 
weekly intervals 
during and 2 months 
after the end of 
radiotherapy 
Breast cancer survivors 
who underwent 
postoperative 
radiotherapy after 
breast-conserving 
surgery (n = 41) 
Inflammatory: 
IL1, IL6, TNF 
 
Fatigue: 
Fatigue Assessment 
Questionnaire (20-item 
tool to assess physical, 
affective, and cognitive 
factors of fatigue) and 
visual analog scale on 
fatigue intensity 
 
Sleep: 
Self-report daily hours of 
sleep 
 
Covariates: none 
mentioned 
None of the cytokines (IL1, IL6, 
TNF) correlated with fatigue. 
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Table 2: Systematic-review of inflammatory markers and fatigue association 
 
 Significantly Associated with Fatigue Not Significantly Associated with Fatigue 
CRP  Alfano et al 2012  
CRP mean = 4.4  8.6 mg/L 
40% of participants had a CRP > 3 mg/L 
Lowest tertile 0.5 mg/L, middle tertile 2.1 mg/L, highest 
tertile 8.0 mg/L; OR highest tertile vs. lowest tertile of 1.8 to 
2.4, depending on the model, p < 0.05 
Fatigue Measure: Piper Fatigue Scale 
Strength: N = 633 
Limitation: cross-sectional, only one assessment of each 
construct, so unable to determine how changes in 
inflammation affect fatigue; selection bias towards healthier 
survivors 
 
Orre et al 2011 
 adj = 0.120, p = 0.020 
Mean hsCRP = 3.13.9 mg/L [0.2-31.0] 
Fatigue Measure: Fatigue Questionnaire (FQ; 11-items 
assessing both physical and mental fatigue) 
N = 299 
 
Reinertsen et al 2011 
Median with chronic fatigue 2.5 mg/L [0.2-23.0] 
Median without chronic fatigue 1.6 mg/L [0.2-31.0],  
p = 0.003 
Fatigue Measure: Fatigue questionnaire (7-item tool to assess 
both mental and physical fatigue) 
Strength: N = 302 
 
Lyon et al 2010 
r = 0.47, p = 0.004 
CRP mean = 3.75 mg/L  3.94 
Fatigue Measure: Brief Fatigue Inventory 
N = 36 
 
Bower et al 2009 
Fatigue duration:  = 0.32; SE = 0.14; p = 0.022 
Effect sizes not reported. 
Fatigue Measure: 
Fatigue Symptom Inventory 
N = 28 
 
Wratten et al 2004 
Spearman’s correlation coefficient-0.456, p < 0.01 
Effect sizes not reported. 
Fatigue Measure: FACT-F 
N = 52 
Fagundes et al 2012 (p = 0.08) 
Fatigued CRP mean = 3.13 mg/L (log10 0.14), Non-fatigued 
CRP mean = 3.24 (log10 0.15); log10 p = 0.88 
Bower et al 2011 (p > 0.09) 
Fatigue Measure: RAND SF-36 
Strength: N = 167 
Limitation: Selection biased possibly towards less-fatigued 
individuals; mostly white sample 
 
Liu et al 2012 
 = 5.124, SE = 4.703, p = 0.3 
Size effects before and during chemotherapy: 
Mean CRP at Baseline 3.09 mg/L, Cycle 1 Week 2 1.54 
mg/L, Cycle 1 Week 3 3.61 mg/L, Cycle 4 Week 2 4.76 
mg/L, Cycle 4 Week 3 3.24 mg/L (p > 0.05) 
Fatigue Measure: Multidimensional Fatigue Symptom 
Inventory-Short Form 
N = 53 
 
Bower et al 2011 
p > 0.9 
Effect sizes not reported. 
Fatigue Measure: Fatigue Symptom Inventory  
Strength: N = 103 
 
Wratten et al 2004 
Week 5 values: Spearman’s correlation coefficient -0.215, p 
= 0.19 
Effect sizes not reported. 
Fatigue Measure: FACT-F 
N = 52 
IL-6 Liu et al 2012 
 = 14.027, SE = 4.194, p = 0.002 
Size effects before and during chemotherapy: 
Baseline mean 2.93 pg/ml compared to Cycle 4 Week 2 
mean 4.21 pg/ml (p < 0.001); baseline compared to Cycle 4 
Week 3 3.37 pg/ml (p < 0.05) 
Fatigue Measure: Multidimensional Fatigue Symptom 
Inventory-Short Form 
 
 
Wratten et al 2004 
Baseline values: Spearman’s correlation coefficient -0.311, p 
Cameron et al 2012 
Non-significant effect sizes not reported. 
Fatigue Measure: SOMA 
Strength: prospective nested-case control design 
Limitation: N = 28, allowing for less statistical power; 
greatly varied period between cancer treatment and analysis 
 
Orre et al 2011 
 adj = -0.015, p = 0.760 
Mean IL-6 among all participants: 0.3 pg/ml 
 
Bower et al 2009 
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= 0.05 
Week 5 values: Spearman’s correlation coefficient -0.367, p 
= 0.03 
Effect sizes not reported. 
Fatigue Measure: FACT-F 
p > 0.30 
Effect sizes not reported. 
Fatigue Measure: 
Fatigue Symptom Inventory 
 
Bower et al 2007 
Baseline IL-6 in fatigued participants: 1.990.21 
Baseline IL-6 in non-fatigued participants: 2.110.16 
p > 0.05 
Fatigue Measure: SF-36 
 
Collado-Hidalgo et al 2006 
p > 0.05 
Effect sizes not reported. 
Fatigue Measure: SF-36 
 
Geinitz et al 2001 
p > 0.05 
Effect sizes not reported. 
Fatigue Measure: Fatigue Assessment Questionnaire 
TNF-  Cameron et al 2012 
Non-significant effect sizes not reported. 
Fatigue Measure: SOMA 
Strength: prospective nested-case control design 
Limitation: N = 28, allowing for less statistical power; 
greatly varied period between cancer treatment and analysis 
 
Bower et al 2007 
Baseline TNF- in fatigued participants: 1.200.43 
Baseline TNF- in non-fatigued participants: 1.210.31 
p > 0.05 
Fatigue Measure: SF-36 
 
Geinitz et al 2001 
p > 0.05 
Effect sizes not reported 
Fatigue Measure: Fatigue Assessment Questionnaire 
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Table 3: Baseline characteristics 
 
Characteristics N (%)* 
Race/ethnicity  
     Non-Hispanic white 60 (88.2) 
     Non-Hispanic black 6 (8.8) 
     Hispanic 2 (2.9) 
Age (years), mean ± SD 61.8  7.2 
Weight (kg), mean ± SD 77.5 ± 15.8 
BMI (kg/m
2
) 29.5  
     Normal (18.5 – 25 kg/m2) 16 (23.2) 
     Overweight (25 – 30 kg/m2) 25 (36.2) 
     Obese (> 30 kg/m
2
) 26 (37.7) 
Education  
     Less than high school 1 (1.5) 
     High school graduate 32 (46.4) 
     College graduate 16 (23.2) 
     Masters/Doctorate graduate 19 (27.5) 
Stage of cancer at diagnosis  
     Stage I 43 (62.3) 
     Stage II 18 (26.1) 
     Stage III 6 (8.7) 
     Stage IV 0 (0) 
Received radiation therapy 14 (20.3) 
Received chemotherapy 37 (53.6) 
Pain Severity (Range 0-10) 
     None (0-3) 
     Mild (3-4) 
     Moderate (5-7) 
     Severe (8-10) 
Pain Intensity (Range 0-10) 
     None (0-3) 
     Mild (3-4) 
     Moderate (5-7) 
     Severe (8-10) 
Worst Pain Score (Range 0-10) 
     No Pain (0-3) 
     Mild (3-4) 
     Moderate (5-7) 
     Severe (8-10) 
Sleep per night (hours), mean ± SD 
 
17 (24.6) 
20 (29.0) 
27 (39.1) 
5 (7.3) 
 
37 (53.6) 
15 (21.7) 
12 (17.4) 
5 (7.3) 
 
2 (2.9) 
17 (24.6) 
35 (50.7) 
15 (21.7) 
6.5 ±1.3 
Quality of sleep  
     Very good 7 (10.2) 
     Fairly good 25 (50.7) 
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* Numbers may not sum to 69 due to missing data, and percentages may not sum to 100% due to 
rounding. 
**The higher the FACIT-Fatigue score (range 0-52), the better the quality of life. 
  
     Fairly bad 24 (34.8) 
     Very bad 2 (2.9) 
FACIT-Fatigue score,** mean ± 
SD 
     Not-fatigued (< 37) 
     Fatigued ( 37) 
37.4 ± 10.6 
30 (43.5) 
38 (55.1) 
CRP1 (mg/L), mean ± SD 
IL6, mean  SD 
TNF-, mean  SD 
3.1 ± 3.7 
2.0  2.1 
2.2  2.9 
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Table 4: Clinical measures in HOPE Study participants and healthy population 
 
 HOPE Study Healthy 
Population 
Inflammatory Biomarkers 
     CRP (mg/L) mean  SD (range) 
     IL-6 (g/mL) mean  SD (range) 
     TNF- (pg/mL) mean  SD (range) 
FACIT-Fatigue 
     Mean  SD 
     Minimum Observed Score 
     25
th
 Percentile 
     50
th
 Percentile (median) 
     75
th
 Percentile 
     Maximum Observed Score 
 
3.13  3.71 (0.08-18.47) 
2.04  2.11 (0.61-16.64) 
2.17  2.90 (0.74-25.19) 
 
37.38 10.63 
11.0 
29.5 
39.0 
47.0 
52.0 
 
<1
57
 
<1-2
57
 
<1 
 
44.17.6*58 
18.0 
41.0 
46.5 
50.0 
52.0 
* General female population norm: healthy sub-population 
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Table 5: Associations between CRP tertiles and cancer-related fatigue overall and stratified 
by covariates 
 
 CRP 
Tertile† 
 
N (%)* Unadjusted 
mean  SE 
p-value 
Adjusted** 
mean  SE 
p-value 
Overall 1 
2 
3 
 
23 (33.3) 
22 (31.9) 
24 (34.8) 
40.71  1.66 
36.77  2.81 
34.89  2.01 
0.169 
39.61  2.91 
36.44  3.47 
38.11  3.30 
0.657 
Cancer Stage 
Lower Stage  
(Stage I) 
      
 
Higher Stage  
(Stage II – III) 
 
 
1 
2 
3 
 
1 
2 
3 
 
 
12 (27.9) 
17 (39.5) 
14 (32.6) 
 
10 (41.67) 
4 (16.7) 
10 (41.7) 
 
41.45  2.86 
35.47  3.46 
38.00  2.57 
0.427 
39.77  2.00 
42.25  4.53 
30.50  2.79 
0.019 
 
36.73  4.00 
33.31  3.52 
39.14  3.30 
0.391 
39.38  3.25 
46.23  5.29 
30.33  4.14 
0.080 
Radiation 
Yes 
 
 
 
No 
 
1 
2 
3 
 
1 
2 
3 
 
 
6 (42.9) 
3 (21.4) 
5 (35.7) 
 
17 (30.9) 
19 (34.6) 
19 (34.6) 
 
40.33  3.17 
31.67  10.53 
40.20  4.42 
0.514 
40.85  2.02 
37.58  2.91 
33.47  2.20 
0.121 
 
34.95  5.43 
38.66  6.40 
42.07  4.91 
0.692 
39.61  3.10 
37.10  3.21 
36.62  3.30 
0.745 
Chemotherapy 
Yes 
 
 
 
No 
 
 
 
1 
2 
3 
 
1 
2 
3 
 
 
13 (35.1) 
16 (43.2) 
8 (21.6) 
 
10 (31.3) 
6 (18.8) 
16 (50.0) 
 
41.25  2.52 
38.56  3.12 
35.63  3.28 
0.518 
40.07  2.19 
32.00  6.15 
34.50  2.60 
0.277 
 
37.54  5.19 
37.75  6.50 
39.72  7.24 
0.922 
44.07  4.68 
35.82  5.91 
40.09  4.48 
0.440 
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BMI Status 
Normal Weight  
(18.5-25 kg/m
2
) 
 
 
Overweight 
(25-30 kg/m
2
) 
 
 
Obese 
(> 30 kg/m
2
) 
 
1 
2 
3 
 
1 
2 
3 
 
1 
2 
3 
 
 
12 (75.0) 
3 (18.8) 
1 (6.3) 
 
9 (36.0) 
9 (36.0) 
7 (28.0) 
 
2 (7.7) 
8 (30.8) 
16 (61.5) 
 
42.31  1.91 
41.67  4.48 
46.00  0.00 
0.855 
39.50  3.38 
37.67  4.23 
36.71  4.60 
0.893 
36.00  6.00 
31.00  5.36 
33.38  2.20 
0.813 
 
49.93  2.64 
44.71  4.80 
45.89  6.16 
0.567 
38.96  6.41 
24.71  11.30 
41.88  7.26 
0.282 
31.53  8.41 
30.06  5.03 
28.66  4.68 
0.910 
Joint Pain 
Intensity 
None – Mild  
 
 
 
Moderate – 
Severe 
 
 
1 
2 
3 
 
1 
2 
3 
 
 
 
19 (37.3) 
15 (29.4) 
17 (33.3) 
 
4 (22.2) 
7 (38.9) 
7 (38.9) 
 
 
 
42.26  1.78 
39.40  2.78 
36.00  2.43 
0.158 
33.75  2.50 
31.14  6.37 
32.14  3.6 
0.946 
 
 
42.04  3.96 
39.50  5.67 
37.99  4.82 
0.684 
45.90  13.55 
34.61  10.91 
41.73  10.45 
0.690 
† CRP tertiles: first tertile  1.235 mg/L, second tertile > 2.321 mg/L and < 2.321 mg/L, third 
tertile  2.321 mg/L 
* Numbers may not sum to 69 due to missing data, and percentages may not sum to 100% due to 
rounding. 
** Adjusted by age, BMI, cancer stage at diagnosis, radiation, chemotherapy, pain intensity, and 
time since cancer diagnosis, with stratification variables removed in respective adjustments. 
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Table 6: Potential risk factors for cancer-related fatigue  
 
 N (%)* Unadjusted 
mean  SE 
p-value Adjusted** 
mean  SE 
p-value 
Cancer Stage 
Lower Stage (Stage I) 
Higher Stage (Stage II – III) 
 
43 (62.3) 
24 (34.8) 
 
37.88  1.81 
36.32  1.86 
0.575  
37.68  1.82 
37.09  2.42 
0.839 
Radiation 
Yes 
No 
 
14 (20.3) 
55 (79.7) 
 
38.43  2.90 
37.10  1.45 
0.681  
39.40  3.50  
37.77  2.59 
0.477 
Chemotherapy 
Yes 
No 
 
37 (53.6) 
32 (46.4) 
 
38.81  1.77 
35.77  1.88 
0.243  
39.52  2.91 
37.65  2.74 
0.506 
BMI Status 
Normal Weight (18.5-25 kg/m
2
) 
Overweight (25-30 kg/m
2
) 
Obese (> 30 kg/m
2
) 
 
16 (23.2) 
25 (36.2) 
26 (37.7) 
 
42.42  1.60 
38.00  2.27 
32.85  2.11 
0.013  
42.42  3.07 
39.41  3.06 
34.88  2.92 
0.065 
Joint Pain Intensity 
None 
Mild 
Moderate 
Severe 
 
37 (53.6) 
15 (21.7) 
12 (17.4) 
5 (7.3) 
 
41.24  1.50 
34.20  2.39 
35.25  2.48 
24.20  7.43 
0.002  
41.68  3.01 
35.88  3.56 
35.89  3.53 
24.52  5.32 
0.011 
Sleep Quality 
Very good 
Fairly good 
Fairly bad 
Very bad 
 
7 (10.1) 
35 (50.7) 
24 (34.8) 
2 (2.9) 
 
44.57  3.74 
38.34  1.69 
34.08  2.31 
34.83  0.17 
0.114  
46.89  4.95 
40.15  2.62 
37.63  2.86 
30.00  7.02 
0.112 
* Numbers may not sum to 69 due to missing data, and percentages may not sum to 100% due to 
rounding. 
* Adjusted by age, BMI, cancer stage at diagnosis, radiation, chemotherapy, pain intensity, and 
time since cancer diagnosis, with stratification variables removed in respective adjustments. 
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Figure 1. Flow of participants through the HOPE Study  
 
 
  
Physician consent given and recruitment 
letter mailed to participant telling them we 
will call them within one week to screen 
N=1397 
 
Screened via 
telephone 
N=1020 
Call in (non-tumor registry 
case) 
N=35 
Not Interested 
N=235 
 No time (n = 77) 
 Not interested (n = 95) 
 Declined/vague reason (n 
= 9) 
 Hang up (n = 6) 
 Lives too far away (n = 14) 
 Unwilling/unable to 
participate in study 
activities (n = 22) 
 Gym too far away (n = 12) 
 
Usual Care Group 
N=61 
 
Exercise Group 
N=60 
 
Completed 6 Months as of 
2/1/13 
N= 44 
Complete 6 Months as of 
2/1/13 
N= 50 
Cases ascertained from tumor registry and 
contacted clinician who was listed on the 
pathology report 
N=1,541 
 
No Physician Consent 
n =144 
 Consent declined (n 
=130) 
 No response (n =14) 
 
Unable to contact/screen 
n = 412 
 Disconnected (n = 62) 
 Wrong number (n = 41) 
 No answer (n = 26) 
 Busy signal (n = 3) 
 Voice message (n = 280) 
 
Ineligible 
N=664 
 Physical illness (n = 89) 
 Mental illness (n = 7) 
 Not feeling well (n = 7) 
 Doesn’t speak English (n = 
29) 
 No transportation (n = 7) 
 Lives out of state (n = 39) 
 Too physically active (n = 
86) 
 No joint pain (BPI < 3) (n = 
147) 
 Not on AI (n = 253) 
 
Completed 12 Months as of 
2/1/13 
N= 30 
Completed 12 Months as of 
2/1/13 
N=27 
Randomized  
N=121 
 
Dropped-Out 
N=1 before 6 
Months 
N = 2 after 6 
Months 
Dropped-Out 
N=3 before 6 
Months 
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Figure 2. Literature Review Process  
 
45 total citations identified after 
independent PubMed search limits:
c-reactive protein AND fatigue AND breast cancer
interleukin AND fatigue AND breast cancer
tumor necrosis factor AND fatigue AND breast cancer
12 duplicates removed
(3 in triple duplicate)
30 citations screened
13 citations excluded at
title and abstract level
2 citations excluded at
full text review
15 citations included in final review
